c-Met + CD3

c-Met + CD3 (also referred to as BS001) is a bispecific antibody (BsAb) designed to simultaneously target the c-Met receptor tyrosine kinase and the CD3 T-cell surface marker. Developed by researchers associated with RemeGen, this therapeutic candidate employs a dual mechanism of action: it redirects T-cell cytotoxicity to c-Met-overexpressing tumor cells by bridging the two cell types, and it acts as a c-Met antagonist by blocking the interaction between Hepatocyte Growth Factor (HGF) and c-Met. This blockade inhibits c-Met phosphorylation and downstream oncogenic signaling. The antibody incorporates a human IgG1 Fc region to enhance its pharmacokinetic profile and extend its circulatory half-life. Preclinical evidence has demonstrated its efficacy in inducing T cell-mediated killing of tumor cells in models of lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and ovarian cancer.

Other names

c-Met/CD3 bispecific antibodyc-Met x CD3 bispecific antibody